|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM317995456 |
| 003 |
DE-627 |
| 005 |
20231225164427.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108637
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1059.xml
|
| 035 |
|
|
|a (DE-627)NLM317995456
|
| 035 |
|
|
|a (NLM)33232825
|
| 035 |
|
|
|a (PII)S1521-6616(20)30797-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Campos-López, Bertha
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients
|b A cross-sectional study
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.06.2021
|
| 500 |
|
|
|a Date Revised 16.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Cardiometabolic status is a key factor in mortality by cardiovascular disease (CVD) in systemic lupus erythematosus (SLE). This study evaluated the association of cardiometabolic risk status with clinical activity and damage in SLE patients. A cross-sectional study was conducted in 158 SLE patients and 123 healthy subjects (HS). Anthropometry, glucose, hs-CRP, lipid profile, oxLDL, sCD36, anti-oxLDL antibodies, and cardiometabolic indexes were evaluated. SLE patients had dyslipidemia, higher sCD36, anti-oxLDL antibodies, hs-CRP, and risk (OR > 2) to present Castelli score ≥ 4.5, HDL-C < 40 mg/dL and LDL-C ≥ 100 mg/dL. Disease evolution time was correlated with glucose and BMI, damage with TG, and clinical activity with TG, TG/HDL-C ratio, and Kannel index. Active SLE patients had risk (OR > 2) to present a Castelli score ≥ 4.5, Kannel score ≥ 3, TG/HDL-C ratio ≥ 3 and HDL-C < 40 mg/dL. In conclusion, SLE patients have high cardiometabolic risk to CVD related to disease evolution time, and clinical activity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cardiometabolic status
|
| 650 |
|
4 |
|a Cardiovascular risk
|
| 650 |
|
4 |
|a Clinical activity
|
| 650 |
|
4 |
|a Dyslipidemia
|
| 650 |
|
4 |
|a SLE
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a CD36 Antigens
|2 NLM
|
| 650 |
|
7 |
|a CD36 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Lipoproteins, LDL
|2 NLM
|
| 650 |
|
7 |
|a oxidized low density lipoprotein
|2 NLM
|
| 650 |
|
7 |
|a C-Reactive Protein
|2 NLM
|
| 650 |
|
7 |
|a 9007-41-4
|2 NLM
|
| 650 |
|
7 |
|a Cholesterol
|2 NLM
|
| 650 |
|
7 |
|a 97C5T2UQ7J
|2 NLM
|
| 650 |
|
7 |
|a Glucose
|2 NLM
|
| 650 |
|
7 |
|a IY9XDZ35W2
|2 NLM
|
| 700 |
1 |
|
|a Meza-Meza, Mónica R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Parra-Rojas, Isela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruiz-Ballesteros, Adolfo I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vizmanos-Lamotte, Barbara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Muñoz-Valle, José Francisco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montoya-Buelna, Margarita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cerpa-Cruz, Sergio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bernal-Hernández, Luis E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a De la Cruz-Mosso, Ulises
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 222(2021) vom: 01. Jan., Seite 108637
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:222
|g year:2021
|g day:01
|g month:01
|g pages:108637
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108637
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 222
|j 2021
|b 01
|c 01
|h 108637
|